SMT201700033B - Combinazione sinergica comprendente avermectine e un fans per l’inibizione dei tumori - Google Patents

Combinazione sinergica comprendente avermectine e un fans per l’inibizione dei tumori

Info

Publication number
SMT201700033B
SMT201700033B SM201700033T SM201700033T SMT201700033B SM T201700033 B SMT201700033 B SM T201700033B SM 201700033 T SM201700033 T SM 201700033T SM 201700033 T SM201700033 T SM 201700033T SM T201700033 B SMT201700033 B SM T201700033B
Authority
SM
San Marino
Prior art keywords
avermectine
fans
tumors
inhibition
combination including
Prior art date
Application number
SM201700033T
Other languages
English (en)
Inventor
Peter Falk
Marie-Lois Ivarsson
Christer Edlund
Original Assignee
Ectin Res Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ectin Res Ab filed Critical Ectin Res Ab
Publication of SMT201700033B publication Critical patent/SMT201700033B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SM201700033T 2011-12-20 2017-01-19 Combinazione sinergica comprendente avermectine e un fans per l’inibizione dei tumori SMT201700033B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1151223 2011-12-20
PCT/SE2012/051456 WO2013095286A2 (en) 2011-12-20 2012-12-20 Synergistic combination for tumor inhibition

Publications (1)

Publication Number Publication Date
SMT201700033B true SMT201700033B (it) 2017-03-08

Family

ID=47561781

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201700033T SMT201700033B (it) 2011-12-20 2017-01-19 Combinazione sinergica comprendente avermectine e un fans per l’inibizione dei tumori

Country Status (11)

Country Link
US (1) US9782424B2 (it)
EP (1) EP2793874B1 (it)
AU (1) AU2012354236B2 (it)
CA (1) CA2895289C (it)
DK (1) DK2793874T3 (it)
ES (1) ES2611086T3 (it)
HR (1) HRP20161799T1 (it)
HU (1) HUE032885T2 (it)
PL (1) PL2793874T3 (it)
SM (1) SMT201700033B (it)
WO (1) WO2013095286A2 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012150543A1 (en) * 2011-05-02 2012-11-08 Universite De Geneve Macrocyclic lactones and use thereof
US20160361298A1 (en) * 2015-06-11 2016-12-15 Globavir Biosciences, Inc. Methods and compositions for treating cancer
US11058700B2 (en) * 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
JP2019523291A (ja) * 2016-08-04 2019-08-22 ネスレ スキン ヘルス エス アー 酒さを治療又は予防するための組成物及びその使用
CN108849912B (zh) * 2018-07-26 2020-06-30 河南省农业科学院植物保护研究所 1,5-二芳基-3-三氟甲基吡唑类化合物在防治农业真菌病害中的应用
CN114948947B (zh) * 2021-12-31 2023-12-29 广州医科大学附属第五医院 硝酸芬替康唑在制备抗肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114376A (en) * 1997-04-30 2000-09-05 Mcgill University Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
GB9916052D0 (en) 1999-07-08 1999-09-08 Pfizer Ltd Anthelmintic compositions
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
EP1428528A1 (en) 2002-09-27 2004-06-16 Tiense Suikerraffinaderij N.V. Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer
JP2005247807A (ja) 2004-03-08 2005-09-15 Japan Science & Technology Agency Nsaidを利用した癌治療用組成物
WO2009060063A1 (en) 2007-11-09 2009-05-14 Intervet International B.V. Anthelmintic combination

Also Published As

Publication number Publication date
CA2895289A1 (en) 2013-06-27
EP2793874B1 (en) 2016-10-19
WO2013095286A3 (en) 2013-11-07
EP2793874A2 (en) 2014-10-29
AU2012354236A1 (en) 2014-07-10
CA2895289C (en) 2020-06-30
HRP20161799T1 (hr) 2017-03-10
AU2012354236B2 (en) 2017-10-05
US9782424B2 (en) 2017-10-10
PL2793874T3 (pl) 2017-06-30
DK2793874T3 (en) 2017-02-06
WO2013095286A2 (en) 2013-06-27
HUE032885T2 (en) 2017-12-28
ES2611086T3 (es) 2017-05-04
US20140371164A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CY2021010I1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4-ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
SMT201700033B (it) Combinazione sinergica comprendente avermectine e un fans per l’inibizione dei tumori
DK2710007T3 (da) Kinasehæmmere
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
CO6970602A2 (es) Inhibidores de quinasa
SMT201500271B (it) Inibitori di neprilisina
DK2540238T3 (da) Specialbyggede patientspecifikke ortopædiske stiftføringer
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
DK2895484T3 (da) Glucosylceramidsynthase-inhibitorer
SMT201600114B (it) Inibitori di beta-secretasi
SMT201500300B (it) Metodi d’uso di inibitori di ALK
BR112014003214A2 (pt) polimorfos inibidores de cinase
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
DK2755963T3 (da) Nye dihydroquinolin-2-on-derivater
DK2917210T3 (da) Alk kinase-inhibitorer
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
BR112013025761A2 (pt) inibidores de hsp90
DK2760886T3 (da) Immunocytokin-kombinationsterapi
DK2547349T3 (da) Kræftterapi med en parvovirus kombineret med en HDAC-hæmmer
FI20115876A0 (fi) Yhdistelmähoito
BR112013031949A2 (pt) conjunto de tubo de subida e método
FI20115640A0 (fi) Yhdistelmähoito
FR2958168B1 (fr) Sonde nasale
IT1402715B1 (it) Sonda di tastaggio